JPMorgan Chase & Co. Boosts Option Care Health (NASDAQ:OPCH) Price Target to $41.00

Option Care Health (NASDAQ:OPCH) had its target price hoisted by JPMorgan Chase & Co. from $40.00 to $41.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 18.87% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. UBS Group started coverage on shares of Option Care Health in a research report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target for the company. Jefferies Financial Group raised Option Care Health from a “hold” rating to a “buy” rating and upped their target price for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $26.00 to $33.00 in a research note on Monday, January 13th. Barrington Research upped their price objective on shares of Option Care Health from $33.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $30.00 target price (down from $31.00) on shares of Option Care Health in a report on Friday, January 10th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Option Care Health has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Option Care Health Stock Performance

NASDAQ OPCH traded down $0.11 on Thursday, reaching $34.49. The stock had a trading volume of 195,761 shares, compared to its average volume of 1,582,669. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The company has a market cap of $5.70 billion, a P/E ratio of 29.01, a price-to-earnings-growth ratio of 2.30 and a beta of 1.33. The firm has a fifty day moving average of $29.38 and a two-hundred day moving average of $28.14. Option Care Health has a 1-year low of $21.39 and a 1-year high of $34.85.

Insider Buying and Selling at Option Care Health

In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $33.26, for a total value of $1,030,926.96. Following the completion of the transaction, the insider now owns 44,974 shares of the company’s stock, valued at $1,495,835.24. The trade was a 40.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.64% of the company’s stock.

Hedge Funds Weigh In On Option Care Health

A number of large investors have recently modified their holdings of OPCH. Westfield Capital Management Co. LP raised its position in Option Care Health by 10.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company’s stock worth $203,204,000 after purchasing an additional 599,589 shares during the period. Global Alpha Capital Management Ltd. increased its stake in Option Care Health by 108.3% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 49,818 shares of the company’s stock worth $1,559,000 after purchasing an additional 25,905 shares during the period. Graypoint LLC purchased a new stake in shares of Option Care Health during the fourth quarter valued at approximately $1,161,000. Victory Capital Management Inc. boosted its position in Option Care Health by 4,432.8% during the 3rd quarter. Victory Capital Management Inc. now owns 1,621,593 shares of the company’s stock valued at $50,756,000 after buying an additional 1,585,818 shares during the period. Finally, Barclays PLC increased its position in shares of Option Care Health by 180.1% in the third quarter. Barclays PLC now owns 310,194 shares of the company’s stock valued at $9,708,000 after acquiring an additional 199,454 shares during the period. 98.05% of the stock is owned by hedge funds and other institutional investors.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.